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Kratak sadr`aj: Pacijenti sa hipertenzivnim sr~anim obolje -
nji ma imaju povi{ene koncentracije N-terminalnog pro-B-
tipa natriuretskog peptida (NT-proBNP). Cilj rada bio je da se
izvr{i evaluacija razlika u NT-proBNP kod pacijenata sa dugo -
godi{njom arterijskom hipertenzijom i znacima hi per tenzivne
kardiomiopatije. Ispitivanje je obuhvatilo tri gru pe sa po 50
ispitanika: zdrave osobe (kontrolna gru pa), paci jente sa arte -
rijskom hipertenzijom i normalnom sistol nom funkcijom leve
komore (grupa 1) i pacijente sa dugo godi{njom arterij skom
hipertenzijom i znacima hiperten zivne kardiomiopatije sa
oslabljenom sistolnom funkcijom leve komore (grupa 2).
Dobijeni podaci pokazali su da NT-proBNP u grupi 1 kao i u
grupi 2 veoma dobro koreli{e (Pearsonov test) sa CRP (grupa
1: r = 0,8424; grupa 2: r = 0,6650), sistolnim pritiskom
(gru pa 1: r = 0,7213; grupa 2: r = 0,4856), dijastolnim pri -
tiskom (grupa 1: r = 0,4282; grupa 2: r = 0,3989) i
ejekcio nom frakcijom (grupa 1: r = –0,7390; grupa 2: r =
0,9111). ROC analiza je pokazala da se AUC izme u kon -
trolne grupe i grupe 1 za NT-proBNP (0,912) zna~ajno ne
razlikuje (p > 0,05) od AUC za sistolni (0,924) i dijastolni
pritisak (0,937). Na osnovu cutoff vrednosti za NT-proBNP
od 5,89 pmol/L mogu se pouzdano razlikovati pacijenti u
grupi 1 od kontrol ne grupe, dok se pomo}u cutoff vrednosti
od 21,67 pmol/L pouzdano razdvajaju pacijente iz grupe 1 i
grupe 2 (u oba slu~aja AUC su 1,000). Pacijenti u grupi 2
koji su pripadali II i III New York Heart Association (NYHA)
klasi su imali zna ~aj no vi{e vrednosti NT-proBNP od onih u I
Introduction
Identification of patients with arterial hyperte n -
sion and onset heart failure through the determi -
nation of the concentration of N-terminal pro-B-type
natriuretic peptide (NT-proBNP) allows timely inten -
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Summary: Patients with hypertensive heart disease have
elevated concentrations of N-terminal pro-B-type natriuretic
peptide (NT-proBNP). The aim of our study was to evaluate
NT-proBNP in patients with long-standing hypertension and
in patients with signs of hypertensive cardiomyopathy. The
study included three groups of 50 subjects: healthy persons
(Control Group), patients with hypertension and normal left
ventricular systolic function (Group 1) and pa tients with long-
standing hypertension and signs of hyper tensive cardiomyo -
pathy with impaired left ventricular systolic function (Group
2). Our results show a very good correlation (Pearson’s test)
between NT-proBNP in Group 1 and Group 2 and C-reactive
protein (Group 1: r = 0.8424; Group 2: r = 0.6650), systolic
blood pressure (Group 1: r = 0.7213; Group 2: r = 0.4856),
diastolic blood pressure (Group 1: r = 0.4282; Group 2: r =
0.3989) and ejection fraction (Group 1: r = –0.7390; Group
2: r = 0.9111). ROC analysis revealed that the AUC between
the Control Group and Group 1 for NT-proBNP (0.912) was
not significantly diffe rent (p>0.05) from the AUC for systolic
(0.924) and diastolic pressure (0.937). A cut-off value for NT-
proBNP of 5.89 pmol/L can be used to reliably distinguish
patients of Group 1 from the Control Group, and a cut-off
value of 21.67 pmol/L reliably separates patients from Group
1 and Group 2 (in both cases, the AUC is 1.000). Patients in
Group 2 who belonged to the II and III New York Heart Asso -
ciation (NYHA) class had significantly higher levels of NT-
proBNP than those in NYHA class I (ANOVA test, p=0.001).
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sification of therapy and enables clinical physicians to
prescribe and implement optimal and appropriate
treatment. This significantly improves the quality of
life for these patients, by delaying progression of the
disease, reducing hospitalizations, lowering the eco -
nomic burden of health care and the costs of hospital
treatment. Detection of heart failure in its initial or
early stage and stopping the disease progression are
the key concerns for these patients (1–3).
Elevated blood pressure exerts »surplus« mecha -
nical force, damaging the endothelium of the blood
vessels and disrupting its function, which contributes
to the development of atherosclerosis and its clinical
manifestations. At the same time, hypertension cau -
ses left ventricular hypertrophy, as an independent
factor for the development of arrhythmias, heart fail -
ure and sudden death (4–7).
Heart failure is difficult to diagnose, especially in
its early stages. Typical clinical symptoms such as rapid
breathing, joint swelling and rapid fatigue are often
absent in mild cases. Even when these symp toms are
present, it is often very difficult to clearly identify this
condition, especially in obese and elderly patients with
hypertension. Diagnosis of heart failure in its primary
stage using only clinical criteria in 50% of cases gives
false positive results (8, 9). The most important met -
hods for the diagnosis of heart failure include: echo -
cardiography, radionuclide angiography and magnetic
resonance imaging of the heart. But none of these
methods is completely reliable or repro ducible, and
using them in daily practice is expensive and requires
considerable time. For clinicians there is a legitimate
medical requirement for a biomarker that would be a
reliable and objective test to identify hyper tensive
patients with onset heart failure (10–14).
The aim of our study was to evaluate NT-proBNP
in patients with long-standing hypertension and in pa -
tients with signs of hypertensive cardio myopathy. The
objectives of the present study were twofold: (a) to
determine the relationship between the parameters of
clinical examination and biomarkers (systolic blood
pres sure, diastolic blood pressure, ejec tion fraction, C-
reactive protein and creatinine) and NT-proBNP
concentrations in patients with hyper tensive heart di sea -
se, and (b) to compare the diagnostic performance of
NT-proBNP with that of parameters of clinical exa -
mination and biomarkers with respect to heart failure.
Materials and Methods
Subjects and samples
The study included three groups, each consis -
ting of 50 subjects: healthy persons (Control Group),
patients with hypertension and normal left ventricular
systolic function (Group 1) and patients with long-
standing hypertension and signs of hy pertensive
cardiomyopathy with impaired left ventri cular systolic
function (Group 2). Control Group comprised healthy
adults of both sexes who had been subjected to a
routine systematic health examination at the Institute
of Occupational Medicine, Military Medical Academy,
and voluntary blood donors at the Institute of Trans -
fusion, Military Medical Academy. Patients in Group 1
and Group 2 were treated at the Clinic of Cardiology,
Military Medical Academy, and had a diagnosis of
heart disease. These patients under went a clinical
exa mination which included phy sical exami nation of
the heart with blood pressure, pulse rate, electro car -
dio gram (ECG) and ECHO cardiogram. Left ventri -
cular ejection fraction (EF) was derived from 2-dimen -
sional echocardiography. Blood samples were taken
from all subjects and serum was separated from cells
within 60 minutes of collection and centrifuged at
2028 g (4000 rpm) for 10 min. We measured all the
biomarkers in a single batch at the Institute of Medi -
cal Biochemistry, Military Medical Academy. All study
participants gave written informed consent.
Measurements
All the biomarkers were measured according to
the manufacturer’s instructions. Levels of NT-proBNP
were measured by a one-step enzyme immunoassay
based on electrochemiluminescence technology on
the Elecsys® 2010 platform (Roche Diagnostics). The
total imprecision (as CV) was <7% at concentrations
of 5 to 488 pmol/L. The reference range, as reported
by the manufacturer, was <14.75 pmol/L. Levels of
C-reactive protein (CRP) were measured using the
Behring BN II Nephelometer (Dade Behring/Siemens
Medical Solutions Diagnostics). The reference range,
as reported by the manufacturer, was <3 mg/L. Cre -
atinine concentrations were measured by the kinetic
alkaline picrate method (improved Jaffe reaction) on
a Dimension RxL Max analyzer (Dade Behring/ Sie -
NYHA klasi (ANO VA test, p = 0,001). Ovi podaci ukazuju
na to da je NT-pro BNP koristan biomarker za razlikovanje
pacije nata sa du go godi{njom arterijskom hipertenzijom ko -
jima pre ti za stoj na sr~ana slabost, {to omogu}ava optimi -
zaciju i ade kvatan tretman ovih pacijenata.
Klju~ne re~i: N-terminalni pro-B-tip natriuretskog pepti -
da, hipertenzivna sr~ana oboljenja, hipertenzivna kardio -
mio patija
These data suggest that NT-proBNP is a useful biomarker for
distin guishing patients with long-standing hypertension who
are at risk of heart failure, allowing optimization and proper
treat ment of these patients.
Keywords: N-terminal pro-B-type natriuretic peptide,
hyper tensive heart disease, hypertensive cardiomyopathy 
mens Medical Solutions Diagnostics). The referen ce
range, as reported by the manufacturer, was 53–115
mmol/L (71–115 mmol/L for men and 53–88
mmol/L for women). Inter- and intraassay CVs for
CRP and creatinine were <5%.
Statistical analysis
Data were statistically analyzed using the Med -
Calc®, Ver. 11.3.3.0 package (MedCalc Software,
Mariakerke, Belgium). Adherence to Gaussian distri -
bu tions was assessed by the Kolmogorov-Smirnov
test. Mean, standard deviation (SD), Student’s t-test
and Pearson’s test were used for statistical analysis.
All probabilities were two-tailed and p<0.05 was
regarded as significant. A 95% confidence interval
(CI) was also shown in reported data.
The diagnostic value of serum NT-proBNP, crea -
tinine, CRP, ejection fraction (EF), systolic and dias -
tolic blood pressure for identifying heart failure was
evaluated using receiver operating characteristic
(ROC) curve analysis, and the data are expressed as
area under the curve (AUC; 95% confidence interval,
95% CI; standard error, SE), positive and negative
predictive value (PV). AUC for these variables were
compared, with p<0.05 taken as a significant result.
Results
The control group included 25 women and 25
men aged 50–65 years (⎯x ± SD, 56.3 ± 4.20). Group
1 included 19 women and 31 men aged 50–65 years
(⎯x ± SD, 57.7 ± 4.57), and Group 2 – 17 women and
33 men aged 50–65 years (⎯x ± SD, 58.1 ± 4.82).
The number of patients from Group 2 in a NYHA class
was: I (N = 29), II (N = 16) and III (N = 5). Patients
from Group 2 who belonged to the II and III New York
Heart Association (NYHA) class had significantly
higher levels of NT-proBNP than those with NYHA
class I (ANOVA test, p = 0.001).
In the control group, the mean (SD) values of NT-
proBNP, creatinine, CRP, systolic blood pressure,
diastolic blood pressure and ejection fraction were:
2.794 (1.515) pmol/L, 85.5 (12.4) mmol/L, 2.64
(1.02) mg/L, 126.9 (9.5) mm/Hg, 81.2 (4.9) mm/Hg,
and 67.2 (4.5) %, respectively.
In patients with hypertension (Group 1), the
mean (SD) values of NT-proBNP, creatinine, CRP, sys to -
lic blood pressure, diastolic blood pressure and ejection
fraction were: 9.575 (5.449) pmol/L, 90.9 (13.7)
mmol/L, 2.73 (1.07) mg/L, 146.3 (9.4) mm/Hg, 92.2
(5.0) mm/Hg, and 60.8 (5.3) %, respectively. The
values of NT-proBNP, creatinine, systolic and diastolic
blood pressure were significantly higher, while ejection
fraction values were significantly lower in Group 1 than
in controls. 
In patients with hypertension and cardio myo -
pathy (Group 2), the mean (SD) values of NT-proBNP,
crea tinine, CRP, systolic blood pressure, diastolic
blood pressure and ejection fraction were: 204.60
(84.93) pmol/L, 90.9 (14.3) mmol/L, 4.17 (1.03)
mg/L, 150.5 (6.3) mm/Hg, 95.5 (11.0) mm/Hg,
and 48.0 (6.0) %, respectively. The values of NT-pro -
BNP, CRP and systolic blood pressure were signi fi -
cantly higher, while ejection fraction values were
signi fi cantly lower in Group 2 than in controls and in
Group 1. Creatinine and diastolic blood pressure
were higher in Group 2 only as compared to controls.
In Group 1, NT-proBNP correlated significantly
with all the determined parameters (creatinine, r =
0.3379, 95% CI 0.0657–0.5633; CRP, r = 0.8424,
95% CI 0.7369–0.9079; systolic blood pressure, r =
0.7213, 95% CI 0.5542–0.8325; diastolic blood pres -
sure, r = 0.4282, 95% CI 0.1701–0.6313; ejec tion
frac tion, r = –0.7390, 95% CI –0.8438 – –0.5800). In
Group 2, NT-proBNP correlated significantly with CRP
(r = 0.6650, 95% CI 0.4745–0.7960), systolic blood
pressure (r = 0.4856, 95% CI 0.2396–0.6730), dias -
tolic blood pressure (r = 0.3989, 95% CI 0.1355–
0.6095) and ejection fraction (r = –0.9111, 95% CI
–0.9489 – –0.8478).
Table I Data from ROC analyses for NT-proBNP, creati nine, systolic blood pressure (sBP), diastolic blood pressure (dBP) and
ejection fraction (EF) for comparing patients with hypertension (Group 1) versus Control Group. AUC for NT-proBNP was not











AUC 0.912 0.603 0.924 0.937 0.811
SE 0.0302 0.0565 0.0281 0.0256 0.0434
95% CI 0.838–0.959 0.501–0.700 0.853–0.967 0.869–0.975 0.720–0.882
Sensitivity 94.0 80.0 98.0 100.0 94.0
Specificity 80.0 40.0 68.0 78.0 60.0
Cutoff 4.74 96 140 85 60
(+) PV 82.5 57.1 75.4 82.0 70.1
(–) PV 93.0 66.7 97.1 100.0 90.9
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In order to determine the diagnostic accuracy of
NT-proBNP and the other parameters for detection of
heart failure in the investigated groups of patients,
ROC plots were calculated. The data from ROC ana -
ly ses are presented in Table I–III. ROC plots are shown
in Figures 1–3.
Figure 1 ROC curves for NT-proBNP, creatinine (CRE), 
sys to lic (sBP) and diastolic blood pressure (dBP) and ejec -




















Figure 2 ROC curves for NT-proBNP, creatinine (CRE),
CRP, systolic (sBP) and diastolic blood pressure (dBP) and
ejection fraction (EF) for distinguishing between controls




















Table III Data from ROC analyses for NT-proBNP, CRP, systolic blood pressure (sBP) and ejection fraction (EF) for comparing
patients with hypertension (Group 1) versus patients with hypertension and cardiomyopathy (Group 2). AUC for NT-proBNP









AUC 1.000 0.838 0.631 0.951
SE 0.000 0.0405 0.0556 0.0225
95% CI 0.963–1.000 0.750–0.904 0.528–0.725 0.889–0.984
Sensitivity 100.0 90.0 58.0 100.0
Specificity 100.0 64.0 70.0 76.0
Cutoff 21.67 3.8 145 52
(+) PV 100.0 71.4 65.9 80.6
(–) PV 100.0 86.5 62.5 100.0
Table II Data from ROC analyses for NT-proBNP, creatinine, CRP, systolic blood pressure (sBP), diastolic blood pressure (dBP)
and ejection fraction (EF) for comparing patients with hypertension and cardiomyopathy (Group 2) versus Control Group. AUC













AUC 1.00 0.596 0.867 0.984 0.947 0.999
SE 0.00 0.0567 0.0369 0.0128 0.0235 0.0025
95% CI 0.963–1.000 0.493–0.693 0.785–0.927 0.936–0.998 0.883–0.981 0.962–1.000
Sensitivity 100.0 66.0 94.0 98.0 100.0 100.0
Specificity 100.0 54.0 64.0 90.0 82.0 98.0
Cutoff 5.89 92 3.8 140 85 58
(+) PV 100.0 58.9 72.3 90.7 84.7 98.0
(–) PV 100.0 61.4 0.867 0.984 0.947 0.999
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Discussion
N-terminal proBNP (NT-proBNP) is becoming
more heavily integrated into clinical practice as a dia -
g no stic and prognostic biomarker. Clinical bio marker
testing in the settings of heart failure has three
important goals: 1) to identify possible underlying
(and potentially reversible) causes of heart failure; 2)
to confirm the presence or absence of the heart
failure syndrome; and 3) to estimate the severity of
heart failure and risk of disease progression (13–14). 
We demonstrated that NT-proBNP is an accu -
rate biomarker for distinguishing between patients
with hypertension and patients with hypertension and
cardiomyopathy. The AUC for NT-proBNP was signi -
ficantly different from the AUC for creatinine, CRP,
systolic and diastolic blood pressure and ejection
fraction (p < 0.05) (Table III and Figure 3). The area
under the curve for NT-proBNP was 1.000 (SE =
0.000; 95% confidence interval, 0.963–1.000), and
the cutoff concentration with the highest diagnostic
accuracy was 21.67 pmol/L (sensitivity 100%; speci -
ficity 100%;). Nakamura et al. (6) reported that NT-
proBNP displayed satisfactory accuracy associated
with a high AUC (0.97) with a threshold value of 50
pg/ml (5.9 pmol/L) for the diagnosis of heart failure
in patients with hypertensive heart disease.
We demonstrated, however, that NT-proBNP can
distinguish between healthy subjects and a group of
patients with hypertension in the same way as systolic
blood pressure and diastolic blood pressure. Natriuretic
peptides are moderately increased (20–100%) in some
but not all patients with systemic hypertension as
compared to controls where blood pressure is normal.
The increase of these peptides is related to left
ventricular mass index, left ventricular hypertrophy and
diastolic left ventricular dysfunction. The concen tra -
tions of natriuretic peptide in plasma were not signi -
ficantly increased in hypertensive patients with normal
left ventricular geometry as compared to normotensive
individuals (17, 18).
Several clinical trials have shown that NT-proBNP
is increased in patients with ventricular dysfunction
and that its level is directly correlated with the severity
of disease (I–IV in the New York Heart Association –
NYHA classification). Some of these tests show that
NT-proBNP is a sensitive marker of cardiac function,
which, when on the rise, indicates the presence of
heart failure; on the other hand, when the level of NT-
proBNP is within the normal limits, it excludes cardiac
dysfunction (9, 19). Patients with hypertension and
cardiomyopathy who belonged to the II and III New
York Heart Association (NYHA) class had significantly
higher levels of NT-proBNP than patients in the
NYHA class I. Seino et al. (7) also evaluated NT-pro -
BNP in 105 patients with chronic heart failure, and a
progressive increase in NT-proBNP in propor tion to
the NYHA classification was validated in this study.
Recent data have also confirmed the association
between increased serum concentrations of CRP and
functional limitation and prognosis (but not with the
severity of left ventricular ejection fraction) (20). Va l ues
of CRP and systolic blood pressure were signifi cantly
higher, and the ejection fraction values were signi fi -
cantly lower in the group of patients with hyper tension
and cardiomyopathy than in the healthy indi viduals and
patients with hypertension. 
Conclusion
The presence of elevated levels of NT-proBNP
was more frequent in patients with hypertensive heart
disease than in the group of »healthy« persons (Con -
trol Group). The values of NT-proBNP were signifi -
cantly higher in patients with signs of hypertensive
cardiomyopathy than in the group of patients with
hypertensive heart disease. These data suggest that
NT-proBNP is a useful biomarker for distinguishing
patients with long-standing hypertension who are at
risk of heart failure, allowing optimization and proper
treatment of these patients. Therefore, at this time,
NT-proBNP testing should still be considered only as
part of the diagnostic evaluation in heart failure, but
not the diagnostic definition.
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Figure 3 ROC curves for NT-proBNP, CRP, systolic blood
pressure (sBP) and ejection fraction (EF) for distinguishing
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